The medication management failures at Lord Chamberlain Manor left the resident at severe risk for potentially fatal blood clots during most of August 2025, according to a September inspection report. The resident required Coumadin to prevent clots related to atrial fibrillation and antiphospholipid syndrome.
Nobody could explain why it happened.
The resident's target blood level, measured by INR testing, should have stayed between 2.5 and 3.5 to prevent dangerous clots. Instead, the patient went without any Coumadin doses on August 14, 15, 18, 19, 20, 21, 22, 23, 24, 26, 29, 30 and 31. When blood levels were finally tested September 1, the INR measured just 1.2 — dangerously below the therapeutic range.
"The INR levels were not maintained within the therapeutic level, which put Resident #1 at a higher risk for blood clots," APRN #2 told inspectors during a September 18 interview. The advanced practice nurse called the management failures "a significant medication error."
The facility's own tracking system documented the cascade of missed doses and communication breakdowns. On August 14, the resident received 7 mg of Coumadin, but staff then discontinued the medication without obtaining new orders or scheduling the next required blood test. For the following two and a half weeks, the resident received no blood thinner at all.
MD #2 confirmed the resident "was at an increased risk of blood clots due to the INR was not maintained within the therapeutic range." The doctor said Coumadin should have been ordered continuously to maintain the target INR levels between 2.5 and 3.5.
When staff finally resumed treatment September 1, they increased the dose to 10 mg daily — a significant jump reflecting how far the blood levels had dropped during the medication gap. The resident received Coumadin on September 1 and 2 before being transferred to a hospital September 3 for an unrelated medical event.
The facility's Coumadin Protocol Policy required staff to maintain detailed tracking logs showing INR dates and results, current and new medication orders, the next INR test date, and documentation of physician notification. The policy specifically directed that "the INR therapeutic range must be determined."
None of that happened consistently during August.
Inspectors interviewed the Director of Nursing, Administrator, and RN #2 on September 23, asking them to explain how the resident's blood thinner management had gone so wrong. All three acknowledged the INR results should have been maintained between 2.5 and 3.5.
They could not provide documentation showing the resident's Coumadin had been managed properly to maintain the required therapeutic levels. The interview "failed to identify why the INR levels were not maintained at the ordered levels," inspectors wrote.
The medication errors created immediate jeopardy, the most serious violation level assigned when inspectors find conditions that pose imminent danger to residents. For patients with atrial fibrillation and antiphospholipid syndrome, maintaining proper Coumadin levels is essential to prevent strokes and life-threatening blood clots.
Atrial fibrillation causes irregular heartbeats that can allow blood to pool and form clots, while antiphospholipid syndrome is an autoimmune disorder that makes blood more likely to clot. Together, these conditions require careful medication management to balance clot prevention against bleeding risks.
The inspection revealed systematic failures in the facility's medication tracking and communication systems. Staff discontinued Coumadin without arranging for continued monitoring or new orders. The tracking form that should have guided proper management was not updated. No one scheduled the next required blood test. Multiple doses were missed without apparent recognition of the growing danger.
When the resident's INR finally was tested September 1 after the 17-day gap, the level of 1.2 was 1.3 points below the minimum therapeutic target — a significant deviation that left the patient vulnerable to clots for weeks.
The resident was transferred to a hospital two days after Coumadin was restarted, though inspectors noted this was for an unrelated medical issue. The inspection report does not indicate whether the patient suffered any blood clots during the period when medication levels were inadequate.
Lord Chamberlain Manor's failures affected few residents, but the medication management breakdown created immediate danger for at least one vulnerable patient whose complex medical conditions required precise pharmaceutical monitoring that simply did not occur.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Lord Chamberlain Manor from 2025-09-23 including all violations, facility responses, and corrective action plans.